Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2018 Jan 11

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

Minerva Medica 2018 Jan 11

DOI: 10.23736/S0026-4806.18.05242-4

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Comparisons of three different doses of alirocumab application in patients with hypercholesterolaemia: a meta analysis

Yu-Sheng ZHANG 1, Ye-Hua HAO 1, Hou-Long LUO 2, Bao-Cheng XIE 1, Jian-Ying FU 1, Zhi- Kun ZHOU 1

1 Department of Pharmacy, Guangdong Medical University, Songshan Lake Science and Technology Industry Park, Dongguan, China; 2 Department of Clinical Immunology, Institute of Laboratory Medicine, Guangdong Medical University, Songshan Lake Science and Technology Industry Park, Dongguan, China


PDF  


INTRODUCTION: Low high-density lipoprotein cholesterol (HDL-C) and high low-density lipoprotein cholesterol (LDL-C) levels are associated with incidence of cardiovascular disease (CVD). Alirocumab has been considered as an efficacious, safe and promising therapeutic modality for hypercholesterolemia. The purpose of this study is to compare the differences of the three different doses of alirocumab in patients with hypercholesterolaemia.
EVIDENCE ACQUISITION: Randomized controlled trials were identified from PubMed, EMBASE, PMC and Cochrane-library databases. The inter-comparison of different doses were performed by subgroups analysis. Meta-analyses were performed by the Review Manager 5.3 and STATA 13.0 software.
EVIDENCE SYNTHESIS: A total of nine studies involving 3870 patients were included in this meta-analysis. Alirocumab administered at 75 - 150 mg every 2 weeks (Q2W) resulted in a greater percent change from baseline in LDL-C concentrations [MD, -55.17; 95% CI - 64.35 to -45.99; P<0.05], and HDL-C levels [MD, 7.70; 95% CI 5.94 to 9.46; P<0.05] than other two doses (300 mg every 4 weeks (Q4W), 150 mg every 2 weeks (Q2W) ). There was no difference in achieving the treatment goal of LDL-C (≤1.8 mmol/L), in other serum lipid parameters (total cholesterol (TC), triglyceride (TG)), and in the incidence of adverse events.
CONCLUSIONS: The results demonstrate that alirocumab at a dose of 75 - 150 mg Q2W should be preferred in patients with hypercholesterolaemia.


KEY WORDS: Alirocumab - Hypercholesterolaemia - Meta-analysis

inizio pagina

Publication History

Article first published online: January 11, 2018
Manuscript accepted: January 4, 2018
Manuscript revised: October 23, 2017
Manuscript received: May 3, 2017

Per citare questo articolo

Zhang YS, Hao YH, Luo HL, Xie BC, Fu JY, Zhou ZK. Comparisons of three different doses of alirocumab application in patients with hypercholesterolaemia: a meta analysis. Minerva Med 2018 Jan 11. DOI: 10.23736/S0026-4806.18.05242-4

Corresponding author e-mail

zhikunzhou@126.com